The tweet was deleted by the author.
But we saved everything 🙂.
Arvinas has achieved a significant milestone with the first approval of a PROTAC protein degrader, underscoring the company's leadership in the targeted protein degradation field.
The company noted that CEO Randy Teel, Ph.D., will discuss this regulatory breakthrough and its implications for the future of targeted protein degraders beyond oncology at the Hanson Wade 9th Annual TPD Summit. The update highlights Arvinas's strategic focus and continued innovation within this emerging therapeutic area.
View post on X Loading...
Arvinas recently began dosing participants in a Phase 1/2 clinical trial for its HPK1 PROTAC degrader, representing an early milestone in its protein degradation research here. The company has also released clinical data on its experimental PROTAC LRRK2 degrader at a movement disorders conference here. These developments reflect Arvinas's clinical activity across multiple targets within the PROTAC platform.